MAGELLAN LONGEVITY
HomeNutraceuticals & Cellular Energizers › D-Glucosamine Sulfate

D-Glucosamine Sulfate

Written and medically reviewed by , physiatrist · Last reviewed · How we grade
In one paragraph

D-Glucosamine Sulfate, graded Moderate-evidence on Magellan — the UK Biobank mortality association (HR ~0.85) is observational and has drawn published selection/healthy-user-bias critiques—longevity benefit is unproven. Studied dose: ~1,500 mg/day (sulfate). Magellan links 24 peer-reviewed citations for D-Glucosamine Sulfate. D-Glucosamine sulfate is a salt of glucosamine, an amino monosaccharide the body synthesizes from glucose and uses as a building block for the glycosaminoglycans and proteoglycans that make up joint cartilage.

Source: Annals of the Rheumatic Diseases 2020, PMID 32253185 ↗ · Nutraceuticals & Cellular Energizers · How Magellan grades evidence · Study write-up · evidence confidence: high

Nutraceuticals & Cellular Energizers24 PubMed citations
$18.95 typical listed price — check the live price on Amazon
View D-Glucosamine Sulfate on Amazon ↗   Open in the Magellan store →

What it is

D-Glucosamine sulfate is a salt of glucosamine, an amino monosaccharide the body synthesizes from glucose and uses as a building block for the glycosaminoglycans and proteoglycans that make up joint cartilage. It is among the most widely sold dietary supplements worldwide and is marketed chiefly for osteoarthritis of the knee, where it is classified as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). In some countries prescription crystalline glucosamine sulfate is regulated as a drug, whereas in the United States glucosamine is sold as an over-the-counter supplement (typically 1500 mg/day).

Its role in longevity

Evidence on glucosamine for aging-related joint health is genuinely mixed: in the landmark 3-year randomized trial of prescription crystalline glucosamine sulfate (n=212), placebo patients lost significant knee joint space (−0.31 mm) while glucosamine patients did not (−0.06 mm), with symptoms improving on glucosamine—yet the larger NIH GAIT trial found glucosamine alone no better than placebo overall, a 2018 JAMA meta-analysis found long-term pain control uncertain for all agents, and guidelines split between conditional support (ESCEO) and recommendation against (ACR/AAOS). Separately, large prospective cohorts such as UK Biobank link habitual glucosamine use to lower all-cause mortality (HR 0.85), cardiovascular disease, and type 2 diabetes risk, but these are observational, cannot establish causation, and have drawn published selection- and healthy-user-bias critiques. Safety is generally good, with cautions around warfarin interaction, shellfish allergy, and blood glucose. This evidence describes the glucosamine compound and its mechanisms as studied across many formulations and brands, not this specific commercial product.

Watch: the 495,000-person cohort behind glucosamine's grade — and why observational data isn't proof. 37 sec.

The research

Peer-reviewed studies on the active compound — citations link to PubMed.

“Regular glucosamine use was associated with significantly lower all-cause, cardiovascular, cancer, respiratory and digestive mortality (all-cause HR 0.73).”
Annals of the Rheumatic Diseases 2020 · PMID 32253185
“Higher genetically predicted glucosamine was associated with greater odds of extended parental lifespan, consistent with a causal effect on longevity.”
Mendelian Randomization Analysis 2022 · PMID 35623867
“Glucosamine/chondroitin use was associated with reduced all-cause mortality in a nationally representative U.S. cohort.”
Frontiers in Pharmacology 2020 · PMID 33219063
“In the MOVES trial, glucosamine plus chondroitin had efficacy comparable to celecoxib in reducing pain, stiffness and functional limitation after 6 months in painful knee osteoarthritis, with a good safety profile.”
Annals of the Rheumatic Diseases 2016 · PMID 25589511
“A meta-analysis of randomized controlled trials found glucosamine improved stiffness outcomes and chondroitin relieved pain and physical function versus placebo in osteoarthritis.”
Journal of Orthopaedic Surgery and Research 2018 · PMID 29980200
“Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function.”
J Orthop Surg Res 2018 · PMID 29980200

Research describes the active mechanism and is not a claim about this specific product.

Educational information, not medical advice. This product is not intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if pregnant, nursing, or taking medication.

More in Nutraceuticals & Cellular Energizers

Omega-3 EPA/DHA Fish Oil

Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…

Creatine Monohydrate

Across meta-analyses and randomized trials, creatine monohydrate combined with…

Astaxanthin Softgels

In humans, randomized trials and meta-analyses most consistently show that astaxanthin…

Zinc Picolinate

Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…

See all Nutraceuticals & Cellular Energizers →

FAQ

Does D-Glucosamine Sulfate have scientific evidence?

Yes — its active compound is linked to 24 peer-reviewed studies, summarized and cited above.

Where can I buy D-Glucosamine Sulfate?

You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.

Is D-Glucosamine Sulfate safe?

Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.